Analgesia
Conditions
Brief summary
This is a prospective non-randomized, open-label, single dose (and a second dose if needed), PK study in 25 children age 1-17 years. The proposed number of study participants by subset is: 8 paediatric participants 1-2 years; 8 paediatric participants \>2-6 years and 9 paediatric participants \>6-17 years.
Interventions
COMBINATION_PRODUCTCT001
Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
Sponsors
Cessatech A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study population will receive a target dose of intranasal CT001 corresponding to sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg (and an additional dose 10 -15 minutes after, if needed) prior to an elective surgical, procedure.
Eligibility
Sex/Gender
ALL
Age
1 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Paediatric participants, age 1-17 years at the day of the surgical procedure * Planned for elective surgical procedures (e.g. hernia, orchiopexy, gastroscopy, cystoscopy) * ASA (American Society of Anaesthesiologists) physical status classification system score 1-2 as determined by investigator * Planned for induction of anaesthesia by an intravenous anaesthetic agent, requiring placement of peripheral venous catheter immediately prior to the surgical procedure * Needs premedication before induction of anaesthesia as determined by investigator * Informed consent by the legally acceptable representative(s) * The legally acceptable representative(s) and patients 15-17 years must be able to understand and speak local language * A female participant who has onset of menarche is eligible to participate if she is not pregnant, not breastfeeding and agree to follow the contraceptive guidance during the treatment period for at least 7 days after administration of study treatment.
Exclusion criteria
* Ex-premature infant (born \<37 weeks AND less than 60 weeks post conceptual age at the day of the surgical procedure) * Mental retardation * Abnormal nasal cavity or nasal obstruction * Clinical contraindications to narcotic analgesia including head injury or any condition that can in the opinion of the investigator, deteriorate safety and well-being of the participants, influence PK data or optimal participation in the trial * Medical history including substance or alcohol abuse * Has received treatment with sufentanil and/or ketamine during the last 72 hours prior to surgery * Has planned perioperative administration of sufentanil and/or ketamine * Has or is suspected of having a family or personal history of malignant hyperthermia * Has or is suspected of having allergies to ketamine or sufentanil
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total absorption over time | 0 - 120 minutes | Area under the concentration vs time curve |
| Maximum absorption | 0 - 120 minutes | Peak concentration (Cmax) |
| Distribution | 120 - 240 minutes | Volumen of distribution (Vd) |
| Elimination | 120 - 240 minutes | Half life (T½) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sedation | 0 - 1 hour | Assessment of sedation at the time of placement of the peripheral venous catheter using the University of Michigan Sedation Score |
| Feasibility, (Acceptance of intranasal administration) | 0- 4 hours | Acceptance of the intranasal route of administration by the child, assessed by the child or legally acceptable representative or health care provider. |
| Analgetic effect | 0 - 1 hour | pain intensity by age-appropriate scale in relation to the placement of peripheral venous catheter |
Countries
Denmark
Outcome results
None listed